Pfizer and BioNTech announced on Wednesday that this preliminary data will help them determine a dose level for the vaccine then select which of their multiple vaccine candidates to progress to a larger-scale global Phase 2/3 study, possibly beginning as early as this month.
Pfizer and BioNTech have revealed early positive data from their mRNA-based COVID-19 vaccine programme, securing their place at the forefront of the global race for a successful candidate against the virus.
COVID-19 vaccine made by USA pharmaceutical giant Pfizer and German biotech firm BioNTech says their COVID-19 vaccine shows potential in early human trials, perhaps adding more breathing room to the COVID-19 vaccine business The drug is one of 17 being tested on humans in a global race to find a vaccine that has touched over 10-and-a-half million people so far.
At day 21 after a single injection, the 12 subjects who received 100 µg of BNT162b1 had an RBD-binding IgG GMC of 1,778 units/ml and a SARS-CoV neutralizing GMT of 33, which are 3-times and 0.35-times, respectively, the GMC and GMT of the convalescent serum panel.
Initial clinical data for one of these candidates, BNT162b1, demonstrated that the experimental vaccine was both well tolerated and generated dose-dependant immunogenicity.
Early studies of the vaccine BNT162b1, one of four candidates to fight the virus, which is now being developed by Pfizer, all patients that were vaccinated at 28 days were identified neutralizing antibodies. Stocks traded higher for most of the session amid positive news on a potential coronavirus vaccine.
AstraZeneca's Covid-19 vaccine candidate, developed by researchers from the Oxford University, will likely provide protection against the disease for one year, the British drug maker's CEO told Belgian radio station Bel RTL.
The sudden surge in corona cases has left the scientific community gasping for fresh answers.
Anthony Fauci, the top U.S. expert in infectious diseases, has expressed his concern over the sudden spike of COVID-19 cases in the country, warning of the risk of a greater outbreak if the latest surge is not controlled. The death count rose to 18,213.
A total of 23 COVID-19 vaccine projects have launched clinical trials on humans, says the London School of Hygiene & Tropical Medicine.
"I was glad to see Pfizer put up their phase 1 trial data today".
Smaller biotechnology companies with promising COVID-19 vaccines pose a special challenge for investors, said Justin Onuekwusi, a portfolio manager at Legal & General Group Plc.
"It's been a tremendous amount of work and there's now a lot of pride to see the results start to come forward. That's good news", US Food and Drug Administration (FDA) commissioner Dr Stephen Hahn said on Thursday.